Carcinoma neuroendocrino de células grandes de pulmónanálisis de una serie de once casos en un hospital universitario

  1. Ramón García Gómez
  2. E. Alvarez Fernández
  3. Federico González Aragoneses
  4. María Cebollero Presmanes
  5. N. Moreno
  6. J. A. Arranz Arija
  7. G. Abad
  8. I. Siso
  9. L. Iglesias
  10. Vanesa Pachón Olmos
  11. V. Díaz
  12. Parham Khosravi Shahi
  13. Gumersindo Pérez Manga
Revista:
Oncología

ISSN: 0378-4835

Año de publicación: 2006

Volumen: 29

Número: 8

Páginas: 17-24

Tipo: Artículo

DOI: 10.4321/S0378-48352006000800002 SCOPUS: 2-s2.0-33845601342 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Oncología

Resumen

Purpose: Lung carcinomas with neuroendocrine differentiation are a heterogeneous group of tumors related to typical and atypical carcinoids, neuroendocrine large-cell carcinomas (NLCC) and small-cell lung cancer (SCLC). NLCC comprises less than 5% of non small-cell lung cancer (NSCLC). In this report, we describe a series of NLCC treated in a single institution in the last ten years. Material and methods: Eleven patients diagnosed as having NLCC (5 of them with mixed histology). Results: At diagnosis, the mean age of the patients was 66 years (5 males and 6 females); 4 had localized disease, 5 locally advanced disease, and 2 metastatic disease. Seven patients underwent initial radical surgery (2 of them followed by adjuvant chemotherapy), 1 patient received chemotherapy and radiotherapy, and 3 patients only chemotherapy. Median overall survival for the whole series was 24 months, and the overall 2-year and 5-year survival were 45% and 27% respectively. Conclusion: Our data corroborate the general recommendation of treating NLCC in a similar way as the rest of the non small-cell lung cancer (NSCLC) are treated. Radical surgery is the main treatment for localized tumors. There are no data indicating a worse response of these tumors to radiation therapy or chemotherapy.

Referencias bibliográficas

  • Shepherd FA, Carney DN. Treatment of NSCLC. Chemotherapy. En Textbook of Lung Cancer. International Association for the study of Lung Cancer. 213-242. Edited: Heine H Hansen. Martin Dunitz Ltd. 2000. The Livery House 7-9 Pratt Street. London. NW1. OAE .
  • Carney DN Shepherd FA. Treatment of SCLC: Chemotherapy. En Textbook of Lung Cancer. International Association for the study of Lung Cancer. 261-272. Edited: Heine H Hansen. Martin Dunitz Ltd. 2000. The Livery House 7-9 Pratt Street. London. NW1. OAE .
  • Arrigoni MG, Woolner LB, Bernatz PE. Atipical Carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972; 64:413-421.
  • Travis W, Rush W, Flieder D, et al. Survival analysis of 200 Pulmonary Neuroendocrine Tumors with Clarification of Criteria for Atypical Carcinoid and its separation from Typical Carcinoid. Am J Surg Pathol. 1998; 22(8): 934-944.
  • Travis W, Crrin B, Shimosato Y, Brambilla E. The Histological typing of lung and pleural tumours. WHO/ IASLC classification of lung and pleural tumours. 3rd ed. Berlin: Springer-Verlag; 1999.
  • Iyoda A, Hirosima K, Baba M, Saitoh Y, Ohwada H, Fujisawa T. Pulmonary Large Cell with Neuroendocrine Features are High-Grade Neuroendocrine Tumors. Ann Thorac Surg 2002; 73: 1049-1054.
  • Baylin SB. Neuroendocrine differenciación: A Pronostic Feature of Non-Small Cell Lung Cancer? Jour. Clin. Oncol. 1989; 7(10): 1375-1376.
  • Gazdar AF. Advances in the biology of lung Cancer. Clinical significance of Differentiation Neuroendocrine. Chest. 1989; 96(1) Supplement: 39S-41S.
  • Berendsen HH, De Leij L, Poppema S, et al. Clinical Characterization of Non-Small Cell Lung Cancer Tumours Showing Neuroendocrine Differentiation Features. Jour. Clin. Oncol. 1989; 7:1614-1620.
  • Dresler C, Ritter J, Patterson GA, Ross E, Bailey MS, Wick M. Clinical pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 1997; 63:180-185.
  • Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: A Clinicopathology study of eighty-seven cases. Jour. Thorac. And Cardi. Sur. 2002; 124(2):285-292.
  • Mountain CF. Revisions in the international system for staging lung cancer. Chest.1997; 111:1710-1717.
  • Therasse P, ArbacK SG, Einsenhauer EA, et al. New Guidlines to Evaluate the Response to Treatment in solid tumors. J Natl Cancer Inst. 2000; 92:205-16.
  • Brown WH. A case of a pluriglandular syndrome: Diabetes of bearded women. Lancet. 1928; II:1002-1003.
  • Younossian AB, Bründler MA, Tötsch M. Feasibility of the new WHO classification of pulmonary neuroendocrine tumours. Swiss. Med WKLY. 2002; 132:535-540.
  • Gugger M, Burckhardt E, Kappeler A, Hirsiger H, Laissue JA, Mazzuchelli L. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J Pathol. 2002; 196:408-415.
  • Addis BJ. Neuroendocrine differentiation in lung carcinoma. Thorax 1995; 50:113-115.
  • Carey FA, Save VE. Neuroendocrine differentiation lung cancer. J. Pathol. 1997; 182:9-10.
  • Sundaresan V, Reeve V, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br. J. Cancer. 1991; 64:333-338.
  • Burnett HE, Spedding AV, Pendleton N, et al. Criteria for assessing the neuroendocrine phenotype and ist incidence in non-small cell lung cancer. Int J Oncol. 1993; 3:65-69.
  • Sturm N, Rossi G, Lanteujoul S, et al. Expression of Thyroid Transcription Factor-1 in the Spectrum of Neuroendocrine Cell Lung Proliferations wiht spectial interest in Carcinoids. Hum Pathol. 2002; 33:175-182.
  • Ullman R, Petzmann S, Klemen H, Fraire AE, Hasleton P, Popper HH. The position of Pulmonary Carcionoids within the spectrum of Neuroendocrine Tumors of the lung and other Tissues. Genes, Chrom & CANCER 2002; 34:78-85.
  • Doddoli Ch, Berlasi F, Chetaille B, et al. Large Cell Neuroendocrine Carcinoma of the lung: An Agressive Disease Potentially Treatable with Surgery. Ann Thorac Surg. 2004; 77:1168-1172.
  • Flieder DB, Vazquez MF. Lung Tumors with Neuroendocrine Morphology. A perspective for the new millennium. Radio. Clin. Nort. Am. 2000; 38 (3):563-577.
  • Huang Q, Muzitansky A, Mark E J. Pulmonary Neuroendocrine Carcinomas. A Review of 234 Cases and a Statistcal Analysis of 50 Cases Treated at One Institution Using a Simple Clinicopathologic Classification. Arch Pathol Lab Med 2002; 126:545-553.
  • García Gómez R, Texeira Fernández R, Jara Sánchez C, Gonzalez Beca R, Pérez Manga G. Carcinoide Bronquial. Tumor poco frecuente. Estudio Clínico de 12 casos. Rev Clin Esp. 1989; 185:9-13.
  • Schrevens L, Vansteenkiste J, Deneffe G, et al. Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience. Lung Cancer 2004, 43:39-45.
  • Linnoila R I, Piantadosi S, Ruckdeschel J C. Impact of Neuroendocrine Differentiation in Non-small Cell Lung cancer. Chest 1994; 106(6):367S-371S.
  • Schleusener J T, Tazelaar H D, Jung S, et al. Neuroendocrine Differentiation is an Independent Prognostic Factor in Chemotherapy-Treated Nonsmall Cell Lung Carcinoma. Cancer 1996; 77:1284-1291.
  • Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10:209-219.
  • Harada M, Yokose T, Yoshida J, et al. Inmunohistochemical meuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung. Lung Cancer 2002; 38:177-184.
  • Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra-21, neuron specific enolase and prognostic of non-small cell lung cancer: Prospective study in 621 patients. Lung Cancer. 2001; 31:221-231.
  • Hage R, Seldenrijk K, de Bruin P, van Swieten H, van den Bosch J. Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg. 2003; 23:457-460.
  • PORT Meta-analysis Trialist Group (Stewart LA). Postoperative radiotherapy in non-small-cell lung cancer. Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257-263.
  • Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative Radiotherapy for patients with completely resected Nonsmall Cell Lung Cancer. Cancer 1999; 86:265-273.
  • Lynch TJ. Treatment of Stage III Non-Small-Cell lung Cancer: 1998. Session Chair. A.S.C.O. Educational. 1998; 265-275.
  • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analisys using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995; 311:899-909.
  • Blum RH. Editorial. Adjuvant Chemotherapy for lung Cancer. A new standart of care. N Eng J Med 2004; 350:404-405.
  • The International Adjuvant Lung Cancer Trial Collaborative Group: CisPlatin- Based Adjuvant Chemotherapy in Patients with Completely Resected. N Engl Med 2004; 350:351-60.
  • Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-samall cell lung cancer. N Eng J Med 2005; 352:2589-2597.
  • Douillard J, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up.On behalf of the Adjuvant Navelbine International Trialist Association. Proc Am Soc Clin Oncol 2005, Abstract 7013.
  • Choi NC. Management of Stage III Non-Small-Cell lung Cancer: Progress in Preoperative Chemoradiotherapy. Session Speaker. A.S.C.O. Educational. 1998; 276-289.
  • Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large Cell Neuroendocrine Carcinoma with Neuroendocrine Morphology of the lung: Prognosis after Complete Resection and Systematic Nodal disecction: Ann Thorac Surg. 2003; 75:348-352
  • García Yuste M, Matilla JM, Alvarez Gago T, et al. Pronostic factor in neuroendocrine lung tumors: A Spanish multicentre study. Ann Thorac Surg. 2000; 70:258-263.
  • Paci M, Cavazza A, Anessi V, et al. Large Cell Neuroendocrine Carcinoma of the Lung: A 10-Years Clinicopathologic Retrospective Study. Ann Thorac Surg. 2004; 77:1163-1167.
  • Filosso PL. Large Cell Neuroendocrine Carcinoma (LCNC) of the lung: A dilema. Eur J Cardiothorac Surg. 2003; 24:672.
  • Iyoda A, Hirosima K, Toyozaki T, et al. Adyuvant Chemotherapy for Large Cell Carcinoma with Neuroendocrine Features. Cancer 2001; 92:1108-1112.
  • Mazières J, Daste G, Molinier L, et al. Large cell neuroendocrine carcinoma of the lung: Pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002; 37:287-292.
  • Gazdar AF, Kadoyama C, Venzon D, et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Nat Cancer Institute. Monographs. 1992; 13:191-196.
  • Graciano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict Chemotherapy response in patiens with non-small cell lung cancer. J Cin Oncol. 1989; 7:1398-1406.
Fuente de los datos: Dialnet